Cargando…

Early prediction of functional prognosis in neurofibromatosis type 2 patients based on genotype–phenotype correlation with targeted deep sequencing

Regardless of treatment, the clinical progression of neurofibromatosis type 2 (NF2), particularly in terms of hearing, swallowing, and gait, tend to worsen throughout the patients’ lives. We performed a retrospective analysis of functional outcomes in Japanese NF2 patients to predict their functiona...

Descripción completa

Detalles Bibliográficos
Autores principales: Teranishi, Yu, Miyawaki, Satoru, Nakatomi, Hirofumi, Ohara, Kenta, Hongo, Hiroki, Dofuku, Shogo, Okano, Atsushi, Takayanagi, Shunsaku, Ota, Takahiro, Yoshimura, Jun, Qu, Wei, Mitsui, Jun, Morishita, Shinichi, Tsuji, Shoji, Saito, Nobuhito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9184572/
https://www.ncbi.nlm.nih.gov/pubmed/35681071
http://dx.doi.org/10.1038/s41598-022-13580-9
_version_ 1784724551618265088
author Teranishi, Yu
Miyawaki, Satoru
Nakatomi, Hirofumi
Ohara, Kenta
Hongo, Hiroki
Dofuku, Shogo
Okano, Atsushi
Takayanagi, Shunsaku
Ota, Takahiro
Yoshimura, Jun
Qu, Wei
Mitsui, Jun
Morishita, Shinichi
Tsuji, Shoji
Saito, Nobuhito
author_facet Teranishi, Yu
Miyawaki, Satoru
Nakatomi, Hirofumi
Ohara, Kenta
Hongo, Hiroki
Dofuku, Shogo
Okano, Atsushi
Takayanagi, Shunsaku
Ota, Takahiro
Yoshimura, Jun
Qu, Wei
Mitsui, Jun
Morishita, Shinichi
Tsuji, Shoji
Saito, Nobuhito
author_sort Teranishi, Yu
collection PubMed
description Regardless of treatment, the clinical progression of neurofibromatosis type 2 (NF2), particularly in terms of hearing, swallowing, and gait, tend to worsen throughout the patients’ lives. We performed a retrospective analysis of functional outcomes in Japanese NF2 patients to predict their functional prognosis. We analyzed genotype–phenotype correlation based on genetic data from a cohort of 57 patients with a mean follow-up of 14.5 ± 6.0 years. Their functional outcomes, including hearing, swallowing, and ambulation, were reviewed. Performing a targeted deep sequencing, germline NF2 mutations were identified in 28 patients (49.1%), and mosaic NF2 was identified in 20 patients (20, 35.0%). The functional preservation period and outcome differed significantly depending on clinical/genetic factors. Among these factors, “Truncating”, “Mosaic”, and “Age of symptom onset ≥ 25” had the most significant effects on functional disability. By applying a combination of an NF2 mutation type/location, and age of symptom onset, we classified different degrees of functional preservation and progression, schwannoma growth rate and total interventions per year per patient. The prediction of detailed functional outcomes in NF2 patients can plan better strategies for life-long disease management and social integration.
format Online
Article
Text
id pubmed-9184572
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-91845722022-06-11 Early prediction of functional prognosis in neurofibromatosis type 2 patients based on genotype–phenotype correlation with targeted deep sequencing Teranishi, Yu Miyawaki, Satoru Nakatomi, Hirofumi Ohara, Kenta Hongo, Hiroki Dofuku, Shogo Okano, Atsushi Takayanagi, Shunsaku Ota, Takahiro Yoshimura, Jun Qu, Wei Mitsui, Jun Morishita, Shinichi Tsuji, Shoji Saito, Nobuhito Sci Rep Article Regardless of treatment, the clinical progression of neurofibromatosis type 2 (NF2), particularly in terms of hearing, swallowing, and gait, tend to worsen throughout the patients’ lives. We performed a retrospective analysis of functional outcomes in Japanese NF2 patients to predict their functional prognosis. We analyzed genotype–phenotype correlation based on genetic data from a cohort of 57 patients with a mean follow-up of 14.5 ± 6.0 years. Their functional outcomes, including hearing, swallowing, and ambulation, were reviewed. Performing a targeted deep sequencing, germline NF2 mutations were identified in 28 patients (49.1%), and mosaic NF2 was identified in 20 patients (20, 35.0%). The functional preservation period and outcome differed significantly depending on clinical/genetic factors. Among these factors, “Truncating”, “Mosaic”, and “Age of symptom onset ≥ 25” had the most significant effects on functional disability. By applying a combination of an NF2 mutation type/location, and age of symptom onset, we classified different degrees of functional preservation and progression, schwannoma growth rate and total interventions per year per patient. The prediction of detailed functional outcomes in NF2 patients can plan better strategies for life-long disease management and social integration. Nature Publishing Group UK 2022-06-09 /pmc/articles/PMC9184572/ /pubmed/35681071 http://dx.doi.org/10.1038/s41598-022-13580-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Teranishi, Yu
Miyawaki, Satoru
Nakatomi, Hirofumi
Ohara, Kenta
Hongo, Hiroki
Dofuku, Shogo
Okano, Atsushi
Takayanagi, Shunsaku
Ota, Takahiro
Yoshimura, Jun
Qu, Wei
Mitsui, Jun
Morishita, Shinichi
Tsuji, Shoji
Saito, Nobuhito
Early prediction of functional prognosis in neurofibromatosis type 2 patients based on genotype–phenotype correlation with targeted deep sequencing
title Early prediction of functional prognosis in neurofibromatosis type 2 patients based on genotype–phenotype correlation with targeted deep sequencing
title_full Early prediction of functional prognosis in neurofibromatosis type 2 patients based on genotype–phenotype correlation with targeted deep sequencing
title_fullStr Early prediction of functional prognosis in neurofibromatosis type 2 patients based on genotype–phenotype correlation with targeted deep sequencing
title_full_unstemmed Early prediction of functional prognosis in neurofibromatosis type 2 patients based on genotype–phenotype correlation with targeted deep sequencing
title_short Early prediction of functional prognosis in neurofibromatosis type 2 patients based on genotype–phenotype correlation with targeted deep sequencing
title_sort early prediction of functional prognosis in neurofibromatosis type 2 patients based on genotype–phenotype correlation with targeted deep sequencing
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9184572/
https://www.ncbi.nlm.nih.gov/pubmed/35681071
http://dx.doi.org/10.1038/s41598-022-13580-9
work_keys_str_mv AT teranishiyu earlypredictionoffunctionalprognosisinneurofibromatosistype2patientsbasedongenotypephenotypecorrelationwithtargeteddeepsequencing
AT miyawakisatoru earlypredictionoffunctionalprognosisinneurofibromatosistype2patientsbasedongenotypephenotypecorrelationwithtargeteddeepsequencing
AT nakatomihirofumi earlypredictionoffunctionalprognosisinneurofibromatosistype2patientsbasedongenotypephenotypecorrelationwithtargeteddeepsequencing
AT oharakenta earlypredictionoffunctionalprognosisinneurofibromatosistype2patientsbasedongenotypephenotypecorrelationwithtargeteddeepsequencing
AT hongohiroki earlypredictionoffunctionalprognosisinneurofibromatosistype2patientsbasedongenotypephenotypecorrelationwithtargeteddeepsequencing
AT dofukushogo earlypredictionoffunctionalprognosisinneurofibromatosistype2patientsbasedongenotypephenotypecorrelationwithtargeteddeepsequencing
AT okanoatsushi earlypredictionoffunctionalprognosisinneurofibromatosistype2patientsbasedongenotypephenotypecorrelationwithtargeteddeepsequencing
AT takayanagishunsaku earlypredictionoffunctionalprognosisinneurofibromatosistype2patientsbasedongenotypephenotypecorrelationwithtargeteddeepsequencing
AT otatakahiro earlypredictionoffunctionalprognosisinneurofibromatosistype2patientsbasedongenotypephenotypecorrelationwithtargeteddeepsequencing
AT yoshimurajun earlypredictionoffunctionalprognosisinneurofibromatosistype2patientsbasedongenotypephenotypecorrelationwithtargeteddeepsequencing
AT quwei earlypredictionoffunctionalprognosisinneurofibromatosistype2patientsbasedongenotypephenotypecorrelationwithtargeteddeepsequencing
AT mitsuijun earlypredictionoffunctionalprognosisinneurofibromatosistype2patientsbasedongenotypephenotypecorrelationwithtargeteddeepsequencing
AT morishitashinichi earlypredictionoffunctionalprognosisinneurofibromatosistype2patientsbasedongenotypephenotypecorrelationwithtargeteddeepsequencing
AT tsujishoji earlypredictionoffunctionalprognosisinneurofibromatosistype2patientsbasedongenotypephenotypecorrelationwithtargeteddeepsequencing
AT saitonobuhito earlypredictionoffunctionalprognosisinneurofibromatosistype2patientsbasedongenotypephenotypecorrelationwithtargeteddeepsequencing